Physician profile
Torfay Roman
NPI 1043485790
$25,530.54
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 80% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.32 · 2020: $12.98 · 2021: $171 · 2022: $142 · 2023: $25.00 · 2024: $11K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $8,500 · Travel and Lodging: $1,945 · Food and Beverage: $682 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,926.94 |
| Consulting Fee | $8,500.00 |
| Travel and Lodging | $1,945.07 |
| Food and Beverage | $682.05 |
| Education | $110.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14,468.02 | 2021-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,626.98 | 2024 | |
| Abbvie INC. | $117.58 | 2022 | |
| Mentor Worldwide LLC | $69.42 | 2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Madrigal Pharmaceuticals | $60.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $53.00 | 2024 | |
| Currax Pharmaceuticals LLC | $37.31 | 2022-2023 | Nexletol |
| Intercept Pharmaceuticals, INC. | $22.59 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.57 | 2019 | |
| Gilead Sciences, INC. | $17.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.98 | 2020 | |
| Intra-Sana Laboratories | $12.52 | 2022 | |
| Vivus LLC | $9.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Torfay Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.